Alnylam Pharmaceuticals (ALNY) Status Update summary

R&D Strategy and Innovation

• Accelerated R&D productivity has resulted in five commercial medicines and a robust pipeline with multi-billion dollar opportunities across diverse indications by end of 2025.

• RNAi technology enables highly specific, potent, and reversible gene silencing, supporting infrequent dosing and broad tissue targeting.

• Focus is on diseases with high morbidity/mortality, high-conviction targets, and clear clinical proof of concept, leveraging human genetics and innovative trial design.

• Expansion into new therapeutic areas includes cardiovascular, neuroscience, metabolic, and rare diseases, with a goal to reach every major tissue by 2030.

• Strategic partnerships and internal pipeline growth are prioritized to maximize value and global reach.

Financial and Commercial Performance

• Achieved $1.65B in 2024 net product revenues, up 33% YoY, with a 58% CAGR since 2019 and strong growth in TTR and rare disease franchises.

• 2025 guidance targets $2.05–$2.25 billion in product sales, aiming for sustainable non-GAAP profitability by year-end.

• Maintained $2.7B in cash at year-end 2024, providing a robust financial position for continued R&D investment.

• Commercial presence in 60 countries, with direct operations in 30.

• ≥40% revenue CAGR expected through YE 2025, on track with P5x25 goals.

Pipeline Highlights and Clinical Updates

• Over 25 high-value programs expected in clinic by end of 2025, with 4+ new INDs planned for 2025.

• HELIOS-B phase 3 study for vutrisiran in ATTR cardiomyopathy showed up to 39% reduction in all-cause mortality, supporting regulatory filings and anticipated launch.

• Nucresiran, a next-generation RNAi therapeutic, demonstrated >90% TTR knockdown with twice-annual dosing and is advancing to phase 3 for both cardiomyopathy and polyneuropathy.

• Zilebesiran for hypertension showed significant, consistent blood pressure reduction in phase 2 studies; a global phase 3 cardiovascular outcomes trial is set to begin in 2024.

• Mivelsiran for Alzheimer's and CAA achieved robust, durable APP reduction in CSF with favorable safety, supporting ongoing and planned phase 2 studies.